SYK — Stryker Corporation

Stryker Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Organic Sales Growth: 2.4% globally, with 1.9% in the U.S. and 3.9% internationally.
• Adjusted Earnings Per Share (EPS): $2.60, down $0.24 (8.5%) from Q1 2025, primarily due to the cyber incident impacting sales and manufacturing absorption.
• Adjusted Gross Margin: 63.6%, a decrease of 190 basis points year-over-year.
• Adjusted Operating Margin: 21.1%, down 180 basis points from the previous year.
• Cash from Operations: $581 million, affected by seasonal cash outflows and the cyber incident.
• Full Year Guidance: Maintained expectations for organic net sales growth of 8% to 9.5% and adjusted EPS of $14.90 to $15.10.

2. Strategic Updates and Business Highlights:

• Cyber Incident Recovery: The company restored full operational capacity by April 1, 2026, after a cyberattack disrupted business operations late in Q1.
• M&A Activity: Announced acquisition of Amplitude Vascular Systems, expected to close in Q2, aimed at expanding treatment options in the peripheral vascular market.
• New Business Unit Formation: Launched Ortho Tech by combining Mako and Enabling Technologies with the Orthopaedic Instruments portfolio to enhance customer experience and accelerate innovation.
• Product Performance: Achieved record Q1 installations for Mako systems, with positive surgeon feedback on Mako Shoulder, set for full launch mid-year.

3. Forward Guidance and Outlook:

• Sales Recovery Expectations: Anticipated recovery of lost sales throughout 2026, with a significant catch-up expected in Q2 and further recovery in Q3 and Q4.
• Market Demand: Strong underlying demand in the procedural environment, with healthy hospital capital expenditure and elevated capital order books.
• Margin Expectations: Full-year operating margin guidance remains unchanged despite early-year headwinds from tariffs and the cyber incident.

4. Bad News, Challenges, or Points of Concern:

• Impact of Cyber Incident: The disruption led to delays in revenue recognition and shipment of products, particularly affecting capital-intensive businesses.
• Geopolitical Risks: The ongoing conflict in the Middle East had a modest effect on international growth.
• Tariff and Input Cost Pressures: Increased tariffs and inflationary pressures could impact margins, although the company is actively working to mitigate these costs.

5. Notable Q&A Insights:

• Customer Relationships Post-Cyber Incident: Customers expressed empathy and support for Stryker's handling of the incident, with no significant loss of business reported.
• Market Dynamics: No signs of order slowdown; hospitals remain stable with strong interest in Stryker products.
• M&A Strategy: The company is open to pursuing both incremental and platform acquisitions in the cardiovascular space, with a focus on leveraging existing sales teams for new products.
• Foot & Ankle Market: The Incompass Total Ankle has been launched, but growth is contingent on the approval of associated guides, which are expected soon.

Overall, Stryker remains optimistic about its growth trajectory despite recent challenges, maintaining its full-year guidance and focusing on strategic initiatives to enhance its market position.